Sign In
Buy OVID
$2.44
-0.0100 (-0.408%)
At Close: Jul 17, 2026
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
08:00am, Tuesday, 10'th Oct 2023
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
07:30am, Tuesday, 26'th Sep 2023
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
07:30am, Wednesday, 20'th Sep 2023
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
08:00am, Wednesday, 30'th Aug 2023
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and
3 Very Promising Penny Stocks That Are Flying Under the Radar
09:38pm, Tuesday, 15'th Aug 2023
Warning: while this discussion obviously centers on penny stocks to buy, this subsegment of the market carries astounding risks. While it's difficult to verify, one source has the failure rate of thes
Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue Estimates
10:32am, Friday, 04'th Aug 2023
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
08:00am, Friday, 04'th Aug 2023
NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies
Ovid Therapeutics: Bullish Outlook Strengthened By Positive 2-Year Open-Label Trial Results
02:12am, Tuesday, 13'th Jun 2023
Ovid Therapeutics' TAK-935 has a high potential for positive Phase 3 clinical trial results for both Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). Significant Revenue Potential. The median a
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
09:54am, Friday, 05'th May 2023
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.23 per share a year ago.
Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know
01:42pm, Wednesday, 12'th Apr 2023
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
08:00am, Monday, 10'th Apr 2023
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies a
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
08:00am, Thursday, 09'th Mar 2023
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
10:00am, Friday, 02'nd Dec 2022
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of
Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
08:00am, Tuesday, 27'th Sep 2022
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o
Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:00am, Wednesday, 07'th Sep 2022
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o
